This is research study is for participants with advanced breast or gastrointestinal cancer who have been taking oral chemotherapy medication (Oral Cancer Directed Therapy). This study is to help researchers better understand gaps in assessing oral chemotherapy patient toxicity at home, adherence to treatment and integrate toxicity/adherence reporting.
For patients with advanced breast or gastrointestinal cancer prescribed Oral Cancer Directed Therapy.
Participants will complete ePRO clinic for all medical oncology scheduled provider appointments during the study period per standard practice
Participants between clinic visits, will be asked to complete the oral weekly survey at home via the mobile or web based patient portal. The survey can be completed on a computer, tablet or smartphone at home or on a tablet at the time of scheduled visit.
The first 100 participants to complete the survey will receive a passive care team alert for responses (per DFHCC policy) The second 100 participants to complete the survey will receive an active care team alert for responses.
Adult age 18 or older Male or Female Scheduled visit at DF/HCC within the BOC or GCC Diagnosis of advanced breast cancer or gastrointestinal cancer Prescribed any OCDT within prior 5 days of screening English as the primary language (as documented in the EHR, written or spoken, and patient interpreter needed flag = no) Mobile number listed in EHR to allow participation in ePP portion of the study Women of any pregnancy status Patients diagnosed with an advanced cancer will be eligible to participate in the study until discontinuation of OCDT or death, whichever occurs first
Exclusion Criteria
Adults unable to provide verbal consent Pediatric patients Patients without access to a electronic device (including tablet, computer, aptop or smartphone)
